Association of matrix metalloproteinases with MRI indices of brain ischemia and aging

Neurobiology of Aging

Volumn 31, Issue 12, 2010, Pages 2128-2135

  Romero, José Rafael ^a   Vasan, Ramachandran S ^a,d   Beiser, Alexa S ^a,b,d   Au, Rhoda ^a,d   Benjamin, Emelia J ^a,d   DeCarli, Charles ^c   Wolf, Philip A ^a,d   Seshadri, Sudha ^a,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

Author keywords

Brain aging; Brain MRI; Framingham; MMPs

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGING; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN SIZE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; STROKE;

AGED; AGING; ATROPHY; BIOLOGICAL MARKERS; BRAIN INFARCTION; BRAIN ISCHEMIA; CROSS-SECTIONAL STUDIES; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 78650172662     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.11.004     Document Type: Article

References (44)

1. Adair J.C., Charlie J., Dencoff J.E., Kaye J.A., Quinn J.F., Camicioli R.M., Stetler-Stevenson W.G., Rosenberg G.A. Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 2004, 35(6):e159-e162.
2. Aktas O., Ullrich O., Infante-Duarte C., Nitsch R., Zipp F. Neuronal damage in brain inflammation. Arch. Neurol. 2007, 64(2):185-189.
3. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 1997, 23(5):406-415.
4. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., Lo E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 2000, 20(12):1681-1689.
5. Asahina M., Yoshiyama Y., Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 2001, 20(2):60-63.
6. Bryan R.N., Cai J., Burke G., Hutchinson R.G., Liao D., Toole J.F., Dagher A.P., Cooper L. Prevalence and anatomic characteristics of infarct-like lesions on MR images of middle-aged adults: the atherosclerosis risk in communities study. AJNR Am. J. Neuroradiol. 1999, 20(7):1273-1280.
7. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci. Lett. 1995, 201(3):223-226.
8. Cunningham L.A., Wetzel M., Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005, 50(4):329-339.
9. Das R.R., Seshadri S., Beiser A.S., Kelly-Hayes M., Au R., Himali J.J., Kase C.S., Benjamin E.J., Polak J.F., O'Donnell C.J., Yoshita M., D'Agostino, Decarli C., Wolf P.A. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008, 39:2929-2935.
10. DeCarli C., Maisog J., Murphy D.G., Teichberg D., Rapoport S.I., Horwitz B. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J. Comput. Assist. Tomogr. 1992, 16(2):274-284.
11. DeCarli C., Massaro J., Harvey D., Hald J., Tullberg M., Au R., Beiser A., D'Agostino R., Wolf P.A. Measures of brain morphology and infarction in the Framingham heart study: establishing what is normal. Neurobiol. Aging 2005, 26(4):491-510.
12. Ellison J.A., Barone F.C., Feuerstein G.Z. Matrix remodeling after stroke. De novo expression of matrix proteins and integrin receptors. Ann. N.Y. Acad. Sci. 1999, 890:204-222.
13. Gottschall P.E., Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 1995, 64(4):1513-1520.
14. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., Smith J.W., Liddington R.C., Lipton S.A. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297(5584):1186-1190.
15. Hamann G.F., del Zoppo G.J., von Kummer R. Hemorrhagic transformation of cerebral infarction-possible mechanisms. Thromb. Haemost. 1999, 82(Suppl. 1):92-94.
16. Heijer T., Skoog I., Oudkerk M., de Leeuw F.E., de Groot J.C., Hofman A., Breteler M.M. Association between blood pressure levels over time and brain atrophy in the elderly. Neurobiol. Aging 2003, 24(2):307-313.
17. Horstmann S., Kalb P., Koziol J., Gardner H., Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003, 34(9):2165-2170.
18. Jeerakathil T., Wolf P.A., Beiser A., Massaro J., Seshadri S., D'Agostino R.B., DeCarli C. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004, 35(8):1857-1861.
19. Kawamura J., Terayama Y., Takashima S., Obara K., Pavol M.A., Meyer J.S., Mortel K.F., Weathers S. Leukoaraiosis and cerebral perfusion in normal aging. Exp. Aging Res. 1993, 19(3):225-240.
20. Kobari M., Meyer J.S., Ichijo M., Oravez W.T. Leukoaraiosis: correlation of MR and CT findings with blood flow, atrophy, and cognition. AJNR Am. J. Neuroradiol. 1990, 11(2):273-281.
21. Lorenzl S., Albers D.S., LeWitt P.A., Chirichigno J.W., Hilgenberg S.L., Cudkowicz M.E., Beal M.F. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J. Neurol. Sci. 2003, 207(1-2):71-76.
22. Lorenzl S., Albers D.S., Relkin N., Ngyuen T., Hilgenberg S.L., Chirichigno J., Cudkowicz M.E., Beal M.F. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem. Int. 2003, 43(3):191-196.
23. Matrisian L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990, 6(4):121-125.
24. Messerli F.H. TIMPs, MMPs and cardiovascular disease. Eur. Heart J. 2004, 25(17):1475-1476.
25. Mun-Bryce S., Rosenberg G.A. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am. J. Physiol. 1998, 274(5 Pt 2):R1203-R1211.
26. O'Brien J.T., Ames D. White matter lesions in depression and Alzheimer's disease. Br. J. Psychiatry 1996, 169(5):671.
27. Pantoni L., Garcia J.H. Pathogenesis of leukoaraiosis: a review. Stroke 1997, 28(3):652-659.
28. Peress N., Perillo E., Zucker S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 1995, 54(1):16-22.
29. Rivera S., Tremblay E., Timsit S., Canals O., Ben-Ari Y., Khrestchatisky M. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J. Neurosci. 1997, 17(11):4223-4235.
30. Romanic A.M., White R.F., Arleth A.J., Ohlstein E.H., Barone F.C. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998, 29(5):1020-1030.
31. Roquer J., Campello A.R., Gomis M. Association of lacunar infarcts with small artery and large artery disease: a comparative study. Acta Neurol. Scand. 2004, 110(6):350-354.
32. Rosenberg G.A. Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 2002, 8(6):586-595.
33. Rosenberg G.A., Sullivan N., Esiri M.M. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001, 32(5):1162-1168.
34. Seshadri S., Wolf P.A., Beiser A., Elias M.F., Au R., Kase C.S., D'Agostino R.B., DeCarli C. Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology 2004, 63(9):1591-1599.
35. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., Siwik D.A., Colucci W.S., Sutherland P., Wilson P.W., Vasan R.S. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004, 109(23):2850-2856.
36. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., Siwik D.A., Colucci W.S., Wilson P.W., Vasan R.S. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J. 2004, 25(17):1509-1516.
37. Sykova E., Mazel T., Simonova Z. Diffusion constraints and neuron-glia interaction during aging. Exp. Gerontol. 1998, 33(7-8):837-851.
38. Tan H.K., Heywood D., Ralph G.S., Bienemann A., Baker A.H., Uney J.B. Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol. Cell. Neurosci. 2003, 22(1):98-106.
39. Tayebjee M.H., Nadar S.K., MacFadyen R.J., Lip G.Y. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension relationship to tissue Doppler indices of diastolic relaxation. Am. J. Hypertens. 2004, 17(9):770-774.
40. Uspenskaia O., Liebetrau M., Herms J., Danek A., Hamann G.F. Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels. BMC Neurosci. 2004, 5:37.
41. van Dijk E.J., Prins N.D., Vermeer S.E., Vrooman H.A., Hofman A., Koudstaal P.J., Breteler M.M. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005, 112(6):900-905.
42. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 2003, 348(13):1215-1222.
43. Wakita H., Tomimoto H., Akiguchi I., Kimura J. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol. (Berl.) 1994, 87(5):484-492.
44. Yamauchi H., Fukuda H., Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis. J. Neurol. Neurosurg. Psychiatry 2002, 72(5):576-582.